Valuation: Pelthos Therapeutics Inc.

Market Cap 90.02M 77.71M 72.91M 66.41M 125M 8.61B 127M 855M 335M 4.31B 338M 331M 14.34B P/E 2026 *
-1.51x
P/E 2027 * -9.21x
Enterprise Value 90.02M 77.71M 72.91M 66.41M 125M 8.61B 127M 855M 335M 4.31B 338M 331M 14.34B EV / Sales 2026 *
1.41x
EV / Sales 2027 * 0.8x
Free-Float
51.18%
Yield 2026 *
-
Yield 2027 * -
1 day-5.82%
1 week-10.69%
Current month-9.63%
1 month-4.04%
3 months-3.07%
6 months+42.39%
Current year-16.45%
1 week 25.83
Extreme 25.83
29.8
1 month 25.33
Extreme 25.33
29.8
Current year 18.19
Extreme 18.19
30.99
1 year 18.19
Extreme 18.19
37.5
3 years 4.5
Extreme 4.5
60
5 years 4.5
Extreme 4.5
60
10 years 4.5
Extreme 4.5
60
Date Insider Type Main position Quantity % Market Cap.
7/2/26 A Sell

Director

-558 0.0161%
7/2/26 A Sell

Director

-786 0.0226%
7/2/26 A Sell

Chairman

-797 0.0229%
Change 5-day change 1-year change 3-year change Capi.($)
-5.82%-10.69%+23.57% - 90.02M
+0.25%-3.96%+68.73%+120.06% 1,055B
+0.78%+0.21%+48.53%+50.78% 632B
+0.35%+0.95%+21.11%+66.86% 442B
+0.35%-3.17%+39.53%+40.05% 351B
+0.44%-1.49%+23.71%+38.70% 290B
+0.77%-1.72%-0.83%+9.21% 243B
+1.00%+0.52%+41.46%+58.95% 227B
-0.68%-5.45%-16.42%-53.57% 200B
+0.40%+4.40%+17.36%+81.59% 172B
Average -0.12%-2.37%+26.67%+45.85% 361.26B
Weighted average by Cap. +0.59%-1.87%+39.35%+64.36%

Financials

2026 *2027 *
Net sales 63.75M 55.03M 51.63M 47.03M 88.42M 6.1B 89.65M 605M 237M 3.05B 239M 234M 10.16B 112M 96.88M 90.89M 82.78M 156M 10.73B 158M 1.07B 418M 5.38B 421M 412M 17.88B
Net income -62.08M -53.59M -50.28M -45.8M -86.11M -5.94B -87.3M -589M -231M -2.97B -233M -228M -9.89B -24.96M -21.54M -20.21M -18.41M -34.62M -2.39B -35.1M -237M -92.85M -1.2B -93.69M -91.67M -3.98B
Net Debt - -
Logo Pelthos Therapeutics Inc.
Pelthos Therapeutics Inc. is a biopharmaceutical company focused on commercializing therapeutic products for unmet patient needs. The Company's lead product, ZELSUVMI (berdazimer) topical gel, 10.3%, is used in the treatment of molluscum contagiosum infections (molluscum) in adults and pediatric patients one year of age and older. In addition to ZELSUVMI, the Company has a pipeline of product candidates that utilize its proprietary nitric oxide-based technology platform, NITRICIL. The Company’s product Xepi is a quinolone antimicrobial indicated for the topical treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes in adult and pediatric patients two months of age and older. Its NaV 1.7 is a clinical-stage assets which selectively target the sodium ion-channel. The Company also Xeglyze, which is a is a pediculicide indicated for the topical treatment of head lice infestation in patients six months of age and older.
Employees
92
Date Price Change Volume
17/08/26 $25.90 -5.82% 29,255
14/08/26 $27.50 -5.01% 23,287
13/08/26 $28.95 +0.14% 44,124
12/08/26 $28.91 +0.98% 23,512
11/08/26 $28.63 -1.28% 37,822
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
25.90USD
Average target price
53.14USD
Spread / Average Target
+105.18%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PTHS Stock